EUVIMEDEUVIMED entdecken
Crossref

Opdualag for Metastatic Melanoma

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668g ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo), a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene Proteins B-rafMutation

Stichwörter der Autor:innen

BraftoviCotellicKeytrudaMekinistMektoviOpdivoOpdualagTafinlarTecentriqYervoyZelborafadverse effectsatezolizumabbinimetinibcobimetinib

Substanzen

Proto-Oncogene Proteins B-raf

Zitieren

APA

(2023). Opdualag for Metastatic Melanoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668g

Vancouver

Opdualag for Metastatic Melanoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668g

BibTeX
@article{euvimed2023,
  title = {Opdualag for Metastatic Melanoma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668g}
}
Kostenlos starten →